ARS Pharmaceuticals, Inc.
SPRY
$9.86
$0.313.25%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 142.77M | 112.34M | 97.12M | 89.15M | 2.57M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 142.77M | 112.34M | 97.12M | 89.15M | 2.57M |
| Cost of Revenue | 27.90M | 21.49M | 19.37M | 20.56M | 20.07M |
| Gross Profit | 114.87M | 90.85M | 77.75M | 68.59M | -17.50M |
| SG&A Expenses | 205.66M | 150.19M | 104.82M | 71.68M | 43.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 233.56M | 171.68M | 124.19M | 92.23M | 63.07M |
| Operating Income | -90.79M | -59.34M | -27.07M | -3.08M | -60.51M |
| Income Before Tax | -79.75M | -47.73M | -15.36M | 8.29M | -49.10M |
| Income Tax Expenses | 288.00K | 288.00K | 288.00K | 288.00K | -- |
| Earnings from Continuing Operations | -80.04 | -48.02 | -15.65 | 8.00 | -49.10 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -80.04M | -48.02M | -15.65M | 8.00M | -49.10M |
| EBIT | -90.79M | -59.34M | -27.07M | -3.08M | -60.51M |
| EBITDA | -89.81M | -58.73M | -26.72M | -3.00M | -60.44M |
| EPS Basic | -0.81 | -0.49 | -0.16 | 0.08 | -0.51 |
| Normalized Basic EPS | -0.53 | -0.32 | -0.12 | 0.03 | -0.34 |
| EPS Diluted | -0.90 | -0.58 | -0.25 | -0.01 | -0.51 |
| Normalized Diluted EPS | -0.58 | -0.38 | -0.18 | -0.03 | -0.34 |
| Average Basic Shares Outstanding | 392.63M | 390.85M | 389.32M | 387.74M | 386.48M |
| Average Diluted Shares Outstanding | 414.44M | 412.67M | 411.14M | 409.56M | 386.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |